Drug Trial Radar · NCT00124982
Study of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-biologic DMARDS (Disease Modifying Antirheumatic Drugs) Who Have an Inadequate Response to Anti-TNF Therapy
Last checked: Nov 20, 2026Latest source record: Feb 27, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,286
Actual
Start
Apr 2005
Primary completion
Aug 2009
Study completion Aug 2009
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Jul 29, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to summarize the safety and tolerability of abatacept during 6 months of combined treatment with one or more of the background non-biologic disease modifying anti-rheumatic drugs (DMARDs) approved for rheumatoid arthritis (RA) in subjects with active RA. Secondary objectives assessed the clinical efficacy of combination treatment, including disease activity, physical function, and quality of life outcomes.
Conditions
- Rheumatoid Arthritis
Interventions
AbataceptDrug
IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)Drug
During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
Anti-Tumor Necrosing Factor (TNF) TherapyDrug
Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Short-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to DiscontinuationsTime frame: Days 1-169
- Short-term Period: Number of Participants With AEs of Special InterestTime frame: Days 1-169
- Short-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) CriteriaTime frame: Days 1-169
- Short-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA CriteriaTime frame: Days 1-169
- Short-term Period: Number of Participants With Electrolyte Laboratories Meeting MA CriteriaTime frame: Days 1-169
- Short-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA CriteriaTime frame: Days 1-169
- Short-term Period: Mean Change From Baseline in Systolic and Diastolic Blood PressureTime frame: Day 1 (Baseline) -Day 169
- Short-term Period: Number of Participants With Positive Anti-Abatacept or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Responses by Enzyme-Linked Immunosorbant Assay (ELISA)Time frame: Days 1-169
- Long-term Period: Number of Participants With Death, Serious Adverse Events (SAEs), Related SAEs, SAEs Leading to Discontinuations, AEs, Related AEs, or AEs Leading to DiscontinuationsTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Number of Participants With AEs of Special InterestTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Number of Participants With Hematology Laboratories Meeting Marked Abnormality (MA) CriteriaTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Number of Participants With Liver and Kidney Function Laboratories Meeting MA CriteriaTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Number of Participants With Electrolyte Laboratories Meeting MA CriteriaTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Number of Participants With Other Chemistry and Urinalysis Laboratories Meeting MA CriteriaTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Change From Baseline in Hemoglobin (HGB), Total Protein, and Albumin Over TimeTime frame: BL, Day 365, Day 729
- Long-term Period: Change From Baseline in Hematocrit Over TimeTime frame: BL, Day 365, Day 729
- Long-term Period: Change From Baseline in Erythrocytes Over TimeTime frame: BL, Day 365, Day 729
- Long-term Period: Change From Baseline in Platelets (PLT) Over TimeTime frame: BL, Day 365, Day 729
- Long-term Period: Change From Baseline in White Blood Cells Over TimeTime frame: BL, Day 365, Day 729
- Long-term Period: Change From Baseline in Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), and G-Glutamyl Transferase (GGT) Over TimeTime frame: BL, Day 365, Day 729
- Long-term Period: Change From Baseline in Bilirubin, Blood Urea Nitrogen (BUN), Creatinine, Calcium (Ca), Phosphorus (P), Serum Glucose (Glu), and Uric Acid Over TimeTime frame: BL, Day 365, Day 729
- LT; Change From Baseline in Sodium (Na), Potassium (K), Chloride (Cl) Over TimeTime frame: BL, Day 365, Day 729
- Long-term Period: Mean Sitting Systolic Blood Pressure (SBP) Over TimeTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Mean Sitting Diastolic Blood Pressure (DBP) Over TimeTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Mean Heart Rate (HR) Over TimeTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
- Long-term Period: Mean Temperature (T) Over TimeTime frame: From Day 169 through Day 813, including up to 56 days after the last dose of long-term period abatacept
Locations
148 sites in 10 countries. Site status is shown where the registry gives one.
Local Institution
Birmingham, Alabama
Local Institution
Huntsville, Alabama
Local Institution
Paradise Valley, Arizona
Local Institution
Peoria, Arizona
Local Institution
Tucson, Arizona
Local Institution
Long Beach, California
Local Institution
Palm Springs, California
Local Institution
Palo Alto, California
Local Institution
San Diego, California
Local Institution
Santa Monica, California
Local Institution
Colorado Springs, Colorado
Local Institution
Denver, Colorado
Local Institution
Danbury, Connecticut
Local Institution
Hamden, Connecticut
Local Institution
Trumbull, Connecticut
Local Institution
Washington D.C., District of Columbia
Local Institution
Aventura, Florida
Local Institution
Clearwater, Florida
Local Institution
Fort Lauderdale, Florida
Local Institution
Jupiter, Florida
Local Institution
Largo, Florida
Local Institution
Sarasota, Florida
Local Institution
Atlanta, Georgia
Local Institution
Blue Ridge, Georgia
Local Institution
Macon, Georgia
Local Institution
Morton Grove, Illinois
Local Institution
Evansville, Indiana
Local Institution
Indianapolis, Indiana
Local Institution
Des Moines, Iowa
Local Institution
Kansas City, Kansas
Local Institution
Prairie Village, Kansas
Local Institution
Bowling Green, Kentucky
Local Institution
Louisville, Kentucky
Local Institution
New Orleans, Louisiana
Local Institution
Boston, Massachusetts
Local Institution
Peabody, Massachusetts
Local Institution
Springfield, Massachusetts
Local Institution
Worcester, Massachusetts
Local Institution
Ann Arbor, Michigan
Local Institution
East Lansing, Michigan
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.